首页> 外文期刊>Sage Open Medicine >Treatment procedures and associated medical costs of methicillin-resistant Staphylococcus aureus infection in Japan: A retrospective analysis using a database of Japanese employment-based health insurance
【24h】

Treatment procedures and associated medical costs of methicillin-resistant Staphylococcus aureus infection in Japan: A retrospective analysis using a database of Japanese employment-based health insurance

机译:在日本的治疗程序和相关的甲氧西林金黄色葡萄球菌感染的医疗费用:使用日本就业的健康保险数据库进行回顾性分析

获取原文
           

摘要

Objectives: This study aimed to determine the patient characteristics, treatment procedures, and medical costs of methicillin-resistant Staphylococcus aureus infections in clinical practice in Japan. Methods: Using the MinaCare database of healthcare information covering nearly 3 million individuals, of which 90% were aged 20–59 years, we extracted and analyzed data of patients who were aged ?15 years and diagnosed with methicillin-resistant S. aureus during hospitalization between April 2010 and August 2015. Results: A total of 684 patients with methicillin-resistant S. aureus infection were listed in the database, of which 365 were eligible to be included in this study. Mean patient age was 52.9 years, and 31.5% of the patients were females. Methicillin-resistant S. aureus bacteremia was the most common methicillin-resistant S. aureus infection (32.9%) with a mean age of 48.5 years, followed by pneumonia (24.1%) with a mean age of 61.0 years and methicillin-resistant S. aureus surgical site infection (6.3%) with a mean age of 49.7 years. Vancomycin was the most frequently prescribed anti–methicillin-resistant S. aureus drug used as the first-line therapy (68.5%), followed by teicoplanin (14.2%), linezolid (7.9%), arbekacin (5.8%), and daptomycin (3.6%). The mortality rate was 11.0%, and the mean treatment duration was 13.3 days. The median total medical cost per patient was US$5083. The median treatment cost for methicillin-resistant S. aureus bacteremia was the highest among the methicillin-resistant S. aureus infections at US$9099, followed by methicillin-resistant S. aureus pneumonia at US$3676 and surgery site infections at US$2084. Conclusion: Although the proportion of patients with methicillin-resistant S. aureus is very small in the employment-based health insurance database, methicillin-resistant S. aureus bacteremia is the most common methicillin-resistant S. aureus infection in the working-age population and requires the highest medical cost. Methicillin-resistant S. aureus pneumonia is more common in the elderly and is a cause of high mortality.
机译:目的:本研究旨在确定日本临床实践中耐甲氧西林耐金黄色葡萄球菌感染的患者特征,治疗程序和医疗费用。方法:使用涵盖近300万个体的医疗保健信息的Minacare数据库,其中90%为20-59岁,我们提取和分析了年龄衰老的患者的数据并在住院期间诊断患有甲氧西林的金黄色葡萄球菌结果在2010年4月至2015年8月期间。结果:数据库中列出了684例耐药性S. aureus感染患者,其中365名有资格包含在本研究中。平均患者年龄为52.9岁,31.5%的患者是女性。耐甲氧西林的金黄色葡萄球菌菌血症是最常见的甲氧西林抗性S. aureus感染(32.9%),平均年龄为48.5岁,其次是肺炎(24.1%),平均年龄为61.0岁和甲氧西林抗性。金黄色葡萄球菌手术部位感染(6.3%),平均年龄为49.7岁。 Vancomycin是最常见的抗甲氧基蛋白抗性S.金黄色葡萄球菌药物用作一线疗法(68.5%),其次是Teicoplanin(14.2%),Linezolid(7.9%),Arbekacin(5.8%)和达达胺( 3.6%)。死亡率为11.0%,平均处理持续时间为13.3天。每个患者的中位数医疗费用为5083美元。耐甲氧胞菌的耐药菌菌菌的中位数治疗成本是甲氧西林抗性S. aureus感染的最高,其次为9099美元,其次是3676美元的甲氧西林肺炎金黄色葡萄球菌,并且手术遗址感染为2084美元。结论:虽然耐甲氧西林耐药患者的比例在基于就业的健康保险数据库中非常小,但耐甲氧西林的S.UUREUS菌血症是工作年龄人口中最常见的甲氧西林抗性S. aureus感染并且需要最高的医疗费用。耐甲氧胞素抗病患者在老年人中更常见,是死亡率高的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号